Article
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
British journal of clinical pharmacology - 1 Nov 2015
Hertz Daniel L, Snavely Anna C, McLeod Howard L, Walko Christine M, Ibrahim Joseph G, Anderson Steven, Weck Karen E, Magrinat Gustav, Olajide Oludamilola, Moore Susan, Raab Rachel, Carrizosa Daniel R, Corso Steven, Schwartz Garry, Peppercorn Jeffrey M, Evans James P, Jones David R, Desta Zeruesenay, Flockhart David A, Carey Lisa A, Irvin William J
Abstract excerpt
AIMS: A prospectively enrolled patient cohort was used to assess whether the prediction of CYP2D6 phenotype activity from genotype data could be improved by reclassification of diplotypes or alleles. METHODS: Three hundred and fifty-five patients receiving tamoxifen 20 mg were genotyped for CYP2D6 and tamoxifen metabolite concentrations were measured. The endoxifen : N-desmethly-tamoxifen metabolic ratio, as a...
Topics
Join the communities discussing this publication.